Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis

Little is known about the immuno-inflammatory response to Tocilizumab and its association with outcome in critically-ill SARS-CoV2 pneumonia. In this multicenter retrospective cohort of SARS-CoV-2 patients admitted to three intensive care units between March and April 2020, we matched on gender and...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbina, Tomas, Lavillegrand, Jean-Rémi, Garnier, Marc, Mekinian, Arsene, Pacanowski, Jerome, Mario, Nathalie, Dumas, Guillaume, Hariri, Geoffroy, Pilon, Antoine, Darrivère, Lucie, Fartoukh, Muriel, Guidet, Bertrand, Maury, Eric, Leblanc, Judith, Chantran, Yannick, Fain, Olivier, Lacombe, Karine, Voiriot, Guillaume, Ait-Oufella, Hafid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841634/
https://www.ncbi.nlm.nih.gov/pubmed/35089113
http://dx.doi.org/10.1177/17534259211064602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841634/
https://www.ncbi.nlm.nih.gov/pubmed/35089113
http://dx.doi.org/10.1177/17534259211064602

Ejemplares similares